ENTA position history
The shares of Enanta Pharmaceuticals (ENTA) that Krensavage Asset Management LLC reported in each quarter’s 13F.
Shares held by quarter
New Add Reduce Exit
- 2021 Q3: 936,777 shares, $53M, 16.7% of portfolio
- 2021 Q4: 564,102 shares, $42M, 14.6% of portfolio, Reduce −39.8%
- 2022 Q1: 548,828 shares, $39M, 13.5% of portfolio, Reduce −2.7%
- 2022 Q2: 624,768 shares, $30M, 9.8% of portfolio, Add +13.8%
- 2022 Q3: 589,360 shares, $31M, 9.7% of portfolio, Reduce −5.7%
- 2022 Q4: 594,818 shares, $28M, 8.5% of portfolio, Add +0.9%
- 2023 Q1: 603,301 shares, $24M, 7.4% of portfolio, Add +1.4%
- 2023 Q2: 687,613 shares, $15M, 4.7% of portfolio, Add +14.0%
- 2023 Q3: 735,103 shares, $8.2M, 3.0% of portfolio, Add +6.9%
- 2023 Q4: 742,824 shares, $7M, 2.5% of portfolio, Add +1.1%
- 2024 Q1: 1,124,586 shares, $20M, 8.7% of portfolio, Add +51.4%
- 2024 Q2: 1,251,338 shares, $16M, 7.5% of portfolio, Add +11.3%
- 2024 Q3: 1,498,074 shares, $16M, 8.7% of portfolio, Add +19.7%
- 2024 Q4: 3,615,464 shares, $24M, 14.4% of portfolio, Add +141.3%
- 2025 Q1: 2,116,586 shares, $12M, 6.5% of portfolio, Reduce −41.5%
- 2025 Q2: 2,114,444 shares, $16M, 8.5% of portfolio, Reduce −0.1%
- 2025 Q3: 2,114,444 shares, $25M, 10.8% of portfolio
- 2025 Q4: 2,766,390 shares, $44M, 15.4% of portfolio, Add +30.8%
- 2026 Q1: 2,866,138 shares, $36M, 14.2% of portfolio, Add +3.6%
- 2026 Q2: 2,866,138 shares, $42M, 15.9% of portfolio
- 2026 Q3: 2,866,138 shares, $38M, 14.2% of portfolio
| Holdings date | Value | % of holdings | Shares | Filing date | All 13F holders |
|---|